Sigma Planning Corp Purchases New Position in Cognition Therapeutics, Inc. (NASDAQ:CGTX)

Sigma Planning Corp acquired a new position in shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) during the fourth quarter, HoldingsChannel reports. The institutional investor acquired 28,550 shares of the company’s stock, valued at approximately $53,000.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CGTX. Oppenheimer reiterated an “outperform” rating and set a $9.00 price target on shares of Cognition Therapeutics in a research note on Wednesday, March 27th. B. Riley reissued a “buy” rating and issued a $5.00 target price on shares of Cognition Therapeutics in a research report on Thursday, March 28th.

Cognition Therapeutics Stock Performance

Shares of CGTX opened at $1.93 on Tuesday. Cognition Therapeutics, Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $3.49. The firm has a 50-day simple moving average of $1.93 and a 200-day simple moving average of $1.75. The company has a market capitalization of $75.27 million, a price-to-earnings ratio of -2.24 and a beta of 1.63.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Tuesday, March 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.11. Equities research analysts forecast that Cognition Therapeutics, Inc. will post -0.98 EPS for the current year.

Cognition Therapeutics Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.